RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
In this article, Managing Director Niall O’Donnell, Ph.D. discusses the law that transformed orphan drug development and how one actor’s starring role in its passage spurred 40 years of prolific, life-saving innovation. ...
In this article, Managing Director Tom Melzer breaks down RiverVest's investment strategy, which centers on managing risk and capital efficiency with one goal in mind: a successful and profitable exit that will maximize investor return. ...